Insurance and GLP-1 Coverage

The Insurance Challenge

Getting insurance to cover GLP-1 weight loss medications remains one of the biggest barriers for patients. Despite strong clinical evidence and FDA approval, many insurance plans deny coverage for anti-obesity medications, require lengthy prior authorization processes, or impose step therapy requirements that delay treatment by months.

Medicare Part D currently does not cover anti-obesity medications at all. Many commercial plans that do offer coverage require documented prior authorization, often including proof of failed diet attempts, BMI documentation, and physician letters — a process that can take 2–6 weeks.

The Cash-Pay Alternative

Imbue Health was built specifically for patients who want to bypass the insurance maze. We use manufacturer-direct savings programs — NovoCare (Novo Nordisk) for Wegovy® and Oral Wegovy®, and LillyDirect (Eli Lilly) for Foundayo™ and Zepbound® — to offer fixed cash-pay pricing that's often lower than insurance copays.

Why cash-pay beats insurance for GLP-1

Imbue Health is a cash-pay program — we do not accept or bill insurance. Our patients get immediate access at predictable manufacturer-published prices, with no prior authorisation, no step therapy, and no denial loop. For most patients, this works out to less than what insured patients pay after copays and deductibles.

You'll never wait weeks for an insurance authorisation, never be told mid-treatment that your plan has changed its formulary, and never have your prescription denied. Pricing is fixed, transparent, and the same whether you have insurance or not — because we don't use it.